CENPB and systemic sclerosis: followed 586 patients with RP over a 20‐year period and demonstrated that the presence of both SSc‐specific autoantibodies (e.g. anti‐CENP‐B, anti‐topoisomerase I, anti‐RNAP III, anti‐Th/To) and a scleroderma‐type NVC pattern significantly increased the risk of progression to definite SSc (79.5% developed SSc; median time to progression 4.6 years; HR 60.08 versus patients with neither predictor).75